Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1176924 | 1.00 | HTR6 (0.64) | HTR6SLC6A4MEN1CYP3A4MAPT | |
| SCHEMBL1177387 | 1.00 | HTR6 (0.64) | HTR6SLC6A4MEN1CYP3A4MAPT | |
| SCHEMBL14197987 | 0.86 | HTR6 (0.59) | HTR6SLC6A4MEN1CYP3A4MAPT | |
| SCHEMBL1852834 | 0.83 | GPR84 (0.52) | HTR6SLC6A4GPR84HTR2A | |
| SCHEMBL1849820 | 0.82 | HTR6 (0.47) | HTR6SLC6A4GPR84HTR2A | |
| SCHEMBL1177126 | 0.82 | HTR1D (0.49) | HTR6SLC6A4MEN1KMT2AHTR2A | |
| SCHEMBL1177038 | 0.82 | HTR2C (0.48) | HTR6SLC6A4MEN1CYP3A4MAPT | |
| SCHEMBL1853764 | 0.80 | SLC6A4 (0.57) | SLC6A4 | |
| SCHEMBL1851294 | 0.80 | HTR2A (0.51) | HTR6MEN1KMT2AGPR84HTR2A | |
| SCHEMBL1177649 | 0.79 | GPR84 (0.51) | HTR6SLC6A4CYP3A4GPR84CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881827-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-09-28 | — | — | EP | disclosed |
| US-7888344-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2011-02-15 | — | — | US | disclosed |
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | MAP4K2, PDPK1, DAPK2 | HTR6 1439/4885SLC6A4 3330/4885MEN1 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.